The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
The Optigen AP 3600 can process up to 100 panels, or as many as 3,600 individual allergen results, in one day, and allows for true walk-away time, the firm said.
The Vitros XT MicroSlide technology allows labs to run two tests that are commonly ordered together simultaneously from a single blood sample.
IL said that the rapid basic metabolic panel is designed for testing at the point of care, primarily in hospital emergency departments and clinical laboratories.
The Army previously awarded Abbott $11.3 million to develop a TBI test. Abbott has worked with DoD since 2014 to develop tests to help evaluate potential concussions.
The company plans to partner with manufacturers to bring different POC assay cartridges onto its reader instrument.
The platform enables the assessment of hemoglobin levels at the point of care and quantitatively measures hemoglobin in capillary or venous whole blood.
The firm's CTO Sarah Levy said the Series C funding will enable it to expand R&D activities to develop applications beyond complete blood counts.
The company aims to launch the test, which it believes will improve monitoring and treatment of patients with diabetes, in China within the next two years.
The University of Toronto is developing a platform that enables swapping of various sensing technologies that could measure different analytes in a range of applications.
Researchers at the University of Birmingham in the UK were awarded £275,000 to develop the new test to measure PSA levels better than conventional tests.
The ongoing opioid epidemic has heightened demand among physicians for more frequent and more rapid drug testing.
Under new ownership, the immunology and allergy testing laboratory is looking to raise its profile in the US and overseas.
The kit is for quantitatively measuring the percent of glycated hemoglobin, total cholesterol, high-density lipoprotein, triglycerides, and glucose.
The firm also reaffirmed its previous guidance of 10 percent growth for fiscal 2019.
GenMark got clearance for an assay to detect fungal pathogens from blood cultures of patients with suspected bloodstream infections, and it received clearance for a bacterial assay.
The researchers are developing immuno-selected-reaction monitoring (SRM) mass spec to measure proteins linked to various immunodeficiency disorders.
A deep analysis of data from drug tests performed at Quest over the past six years has helped the company identify which drug tests are needed by clinicians.
In a pair of recent studies, Crescendo put forth new clinical utility data and an age and adiposity-adjusted model for its Vectra DA rheumatoid arthritis test.
The Erytra Eflexis is a fully automated benchtop analyzer for pretransfusion compatibility testing that facilitates multiple lab configurations and features real random access.